studies

HEPATOLOGY, VOLUME 62, NUMBER 1 (SUPPL) AASLD ABSTRACTS 405A
oped for use in studies to validate the utility of these exRNA as
diagnostic markers for HCC.
Disclosures:
The following authors have nothing to disclose: Irene K. Yan, Tushar Patel
385
The radiofrequency ablation is eligible treatment for
the case of hepatocellular carcinoma more than 3 cm
in diameter with Child-Pugh class A or des-gamma-carboxy
prothrombin level less than 200 mAU/mL: Analysis
of 1815 cases in a single center for fourteen-year
experience
Takashi Tanaka, Akira Anan, Daisuke Morihara, Kazuhide
Takata, Keiji Yokoyama, Yasuaki Takeyama, Makoto Irie, Satoshi
Shakado, Tetsuro Sohda, Shotaro Sakisaka; Fukuoka university
school of medicine, Hepatology, Fukuoka, Japan
Background and Aims: Most of the hepatocellular carcinoma
(HCC) more than 3 cm in diameter is categorized into intermediate
stage of Barcelona Clinic Liver Cancer (BCLC) staging
system, and first line treatment in the intermediate stage is recommended
transcatheter arterial chemoembolization (TACE).
Although general indication of radiofrequency ablation (RFA)
treatment for HCC is defined as tumor size less than 3 cm in
diameter, some previous trials described RFA for HCC more
than 3 cm in diameter. The aim of this study was to analyze the
long term outcome and prognostic factors in the patients who
had received RFA treatment for HCC more than 3 cm in diameter.
Methods: A total of 1815 cases with liver tumors, from
April 2000 to September 2014 were received RFA treatment
in Fukuoka University Hospital. Among them, 94 cases were
enrolled in this study, which was defined as patients with single
or multinodular HCC more than 3 cm in diameter. Overall survival
and recurrence rates were analyzed by the Kaplan-Meier
method and risk factors on prognosis was assessed by multivariate
Cox regression hazard model. Results: The median age of
the study population (men 62 and women 32) was 71 (range:
48-88) years old. Patient’s Child-Pugh class was in A (n=72)
and B (n=22) and 77 patients related with viral hepatitis (HBV:
n=4, HCV: n=73). The median tumor size was 3.5 cm in diameter
(range: 3.1-6.2 cm), and the number of tumor was single:
n=51, double: n=20, triple: n=6, more than four: n=7. We
declined “up to 6” group who have the number of the tumor
plus maximal size (cm) less than six, 66 patients were within
up to 6 group. The median serum level of alpha-fetoprotein
(AFP) and des-gamma-carboxy prothrombin (DCP) level was 35
(range: 2-3061) and 99 (range: 8-12502) respectively. Cumulative
overall survival rates at 1-, 3-, 5-, 10-years were 93.4%,
62.7%, 38.4%, and 12.7%, respectively. Cumulative disease
free survival rate at 1-, 3-, 5-, 10-years were 51.4%, 19.4%,
15.3%, and 4.6%, respectively. Multivariate analysis revealed
that factors associated with survival were tumor recurrence free,
(HR=3.428; 95%CI 1.407-11.421, p=0.0044), Child-Pugh
class A (HR=2.136; 95%CI 1.233-3.633, p=0.0084), and
DCP levels less than 200 mAU/mL (HR=1.957; 95%CI 1.198-
3.159, p=0.0078). Multivariate analysis disclosed that without
up to 6 (HR=1.714; 95%CI 1.066-2.708, p=0.027) predicted
higher incidence of developing recurrence. Conclusion: From
our over 1800 RFA experiences in fourteen years, we revealed
that radiofrequency ablation is eligible treatment for the case
of hepatocellular carcinoma more than 3 cm in diameter with
Child-Pugh class A or DCP level less than 200 mAU/ml.
Disclosures:
The following authors have nothing to disclose: Takashi Tanaka, Akira Anan, Daisuke
Morihara, Kazuhide Takata, Keiji Yokoyama, Yasuaki Takeyama, Makoto
Irie, Satoshi Shakado, Tetsuro Sohda, Shotaro Sakisaka
386
Racial Differences in the Presentation and the Incidence
of Hepatocellular Carcinoma (HCC) in a Large Cohort of
Patients with Cirrhosis in the United States
Long H. Nguyen 1 , Changqing Zhao 2,5 , Nghia H. Nguyen 3,2 ,
Joseph K. Hoang 2 , Michael D. Nguyen 2 , Richard H. Le 2 , Peter T.
Nguyen 2,6 , Derek Lin 1 , Vinh D. Vu 2 , Lee Ann Yasukawa 4 , Susan C.
Weber 4 , Mindie H. Nguyen 2 ; 1 Department of Medicine, Stanford
University Medical Center, Palo Alto, CA; 2 Division of Gastroenterology
and Hepatology, Stanford University Medical Center, Palo
Alto, CA; 3 Department of Medicine, University of California, San
Diego, San Diego, CA; 4 Center for Clinical Informatics, Stanford
University School of Medicine, Palo Alto, CA; 5 Department of Cirrhosis,
Institute of Liver Disease, Shuguang Hospital, Shanghai
University of T.C.M., Shanghai, China; 6 School of Medicine, University
of Texas Medical Branch, Galveston, Galveston, TX
Purpose: Cirrhosis regardless of etiology is a significant HCC
risk factor. The purpose of our study is to clarify the largely
unknown role of ethnicity in the development of HCC in patients
with cirrhosis. Methods: We conducted a retrospective cohort
study of 3208 consecutive white (n=1,692), Hispanic (n=772),
Asian (n=614), and black (n=130) patients with cirrhosis seen
at a single university tertiary care center from 2005-2010. Our
primary endpoint was HCC diagnosis by histology or non-invasive
criteria. Results: Among ethnic groups, patients were
similarly aged (54-59 years), mostly male (61-64%), and with
similar baseline MELD scores (17-23), while black patients had
much shorter duration of follow up (22 vs. 31-40 months). At
presentation, the highest HCC prevalence was seen in Asian
(11%) then Hispanic (5%), white (4%), and black patients (4%,
p